DATA GRAPHICS | Data Byte
CHMP recommends five new drugs
Four of the five are already approved in the U.S.
June 20, 2025 8:54 PM UTC
EMA’s CHMP recommended five new products for approval at its June meeting.
Four are already approved in the U.S. for the same indications. The fifth — allogenic stem cell therapy Zemcelpro from Excellthera Inc. — has not yet been submitted to FDA. EMA recommended conditional authorization for the cord-blood derived cell therapy, intended for use in hemopoietic stem cell transplant when no other donor is available. The product has orphan designation in the U.S...